Rezny Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-39,976
Closed -$2.97M 19
2022
Q2
$2.97M Buy
39,976
+5,991
+18% +$450K 1.14% 12
2022
Q1
$3.05M Buy
33,985
+5,739
+20% +$530K 0.99% 13
2021
Q4
$3.16M Buy
28,246
+806
+3% +$97.2K 0.98% 11
2021
Q3
$3.45M Buy
27,440
+23,431
+584% +$3.02M 1.17% 11
2021
Q2
$542K Buy
+4,009
New +$527K 0.19% 13

Other funds holding XBI

Rezny Wealth Management's XBI Position: Q3 2022 in Review

Rezny Wealth Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2022, closing a stake of 39,976 shares — an estimated $2.97M sold.

Rezny Wealth Management first reported a position in XBI in Q2 2021 and held it in 5 quarters. The position peaked at $3.45M in Q3 2021. 704 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

  • Rezny Wealth Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2022 after selling out during the quarter.
  • Rezny Wealth Management sold 39,976 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $2.97M.
  • Rezny Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and held it in 5 quarters.
  • Rezny Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $3.45M in Q3 2021.
  • 704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on Rezny Wealth Management's 13F filing for Q3 2022, filed 28 Oct 2022.